News and Announcements
Alcidion Develops Data Acquisition Technology for NEDA
- Published June 15, 2016 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
15th June 2016, ASX Announcement
Highlights:
- Data Acquisition Technology developed for National Echo Database Australia.
- Collates several million echocardiograms into national database.
Alcidion Group Limited (ASX: ALC) has developed a new technology in partnership with the National Echocardiography Database of Australia (NEDA). The technology extracts, normalises and amalgamates data from Echocardiography (“Echo”) studies performed around Australia into a single, centralised cloud hosted database server. NEDA is headed up by internationally renowned cardiologist, Professor David Playford and the CEO of the Pulmonary Hypertension Society Australia and New Zealand Inc, Associate Professor Geoff Strange.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
